Feb.23, 2020 / Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ? (lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S. This action is being taken after ……
January 23, 2020 / The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved the expanded use of STELARA? (ustekinumab) for the treatment of paediatric patie……
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved a new indication for Revlimid (lenalidomide), in combination with rituximab (anti-……
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq? (atezolizumab) in combination with chemotherapy (Abraxane? [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the init……
Ono Pharmaceutical Co., Ltd. (Osaka, Japan, President and Representative Director: Gyo Sagara;“ONO”) announced today that it has launched Coralan? (generic name: ivabradine hydrochloride)Tablet 2.5mg, 5mg and 7.5mg (“Cor……
November 22, 2029, Merck, today announced that the European Commission has granted a conditional marketing authorization to ERVEBO for active immunization of individuals 28 years of age or older to protect against Ebola ……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
